Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?

Ryder REJ, DeFronzo RA. Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME™: the optimal combination may be metformin, pioglitazone and empagliflozin. Br J Diabetes Vasc Dis 2015;15:151–4. https://doi.org/10.15277/bjdvd.2015.045

Ryder REJ, DeFronzo RA. Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives? Br J Diabetes 2016;16:103–06. https://doi.org/10.15277/bjd.2016.096

Ryder REJ, DeFronzo RA. What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives? Br J Diabetes 2017;17:89–92. https://doi.org/10.15277/bjd.2017.036

Marso SP, Daniels GH, Brown-Frandsen K, et al, LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–22. https://doi.org/10.1056/NEJMoa1603827

Marso SP, Bain SC, Consoli A, et al, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44. https://doi.org/10.1056/NEJMc1615712

Pfeffer, MA, Claggett, B, Diaz, R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247–57. https://doi.org/10.1056/NEJMoa1509225

AstraZeneca. Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk. Press release 23 May 2017. https://www.astrazeneca.com/media-centre/press- releases/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-23052017.html (accessed 12 October 2017).

EASD Virtual Meeting. Webcast: EXenatide Study of Cardiovascular Event Lowering (EXSCEL): primary results. https://www.easd.org/virtualmeeting/home.html#!contentsessions/2628 (accessed 1 November 2017).

Holman RR, Bethel MA, Mentz RJ, et al, EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228–39. https://doi.org/10.1056/NEJMoa1612917

Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? Diabetes Care 2017;40:813–20. https://doi.org/10.2337/dc16-2736

Intarcia. Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO trial for ITCA 650, an investigational therapy for type 2 diabetes. Press release 6 May 2016. https://www.intarcia.com/media/press-releases/2016-may-6-cardiovascular-safety.html (accessed 1 November 2017).

Ryder REJ. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabet Med 2013;30:1148–55. https://doi.org/10.1111/dme.12301

Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab 1 June 2017. https://doi.org/10.1111/dom.13028. [Epub ahead of print].

European Medicines Agency. Victoza (liraglutide). Summary of product characteristics. Update 14/09/2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf (accessed 12 October 2017).